is glp-1 safe receptor agonists Safety risks in the GLP-1

The SURMOUNT-OSA trial reported that tirzepatide reduced the apnea-hypopnea index by 25% to 29% over 52 weeks in individuals with obesity and moderate to severe OSA, compared with a reduction of 5.3% to 5.5% in the placebo group, regardless of the use of positive airway pressure therapy (19)

You do not need to prime before every injection

GLP-1R, a core member of the GPCR family, is widely present on the surfaces of various cells in the human body

Nondigestible carbohydrates, butyrate, and butyrate-producing bacteria

These numbers are meaningfully higher than tirzepatide discontinuation rates and represent an important consideration for researchers planning long-term protocols